Skip to main content
OpenTrials
Completed

NCT Number: NCT06698731

A Randomized, Active-Controlled, Double-Masked, Crossover Study to Evaluate the Clinical Performance of Deseyne (Vifilcon C) Daily Disposable Soft Contact Lens for Presbyopia Extended Depth of Focus (EDOF)

The goal of this clinical trial is to learn if the contact lens we are testing will work to extend the range of clear focus at distance to provide an increase in clear vision at closer ranges without the additional need for bifocal lenses or reading correction.

The clinical study will compare the use of the test lens for extended range of focus (far to near) to a standardized contact lens designed for distance vision (far) (ie. Walking, driving, etc., where closer-in vision is not anticipated to be helpful, particularly in a population of users in the age range of 45-70.

We will also learn about the effectiveness of the lens to maintain good contrast in low illumination such as during evening and night-time periods.

The main questions we aim to address in the study are:

*. Does the contact lens provide adequate vision at distances closer to the patient such as during reading or computer usage?

* Whether the contact lens in use introduces any visual disturbance or safety concern as compared to a currently designed lens for distance use?

The study is designed to be conducted in the doctor's office:

* Using electronic vision measuring equipment familiar to the user. * A total of two visits are necessary to complete he study * All patients will experience using the test lens as well as the control lens during the study * No contâct lenses will be given to the study patients to take home. * It is anticipated that the total amount of time of participation in the study will be approximately 3 hours of your time over two separate visits.

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Omega VisionCenter PA, Longwood, Florida, United States

Loading trial locations.

About this study

The Deseyne daily disposable soft contact lens is intended for the correction of presbyopia and considered to be one of the growing class of extended depth of focus (EDOF) devices that uses a variety of strategies to provide useful intermediate and near vision. The lens is manufactured with vifilcon C material containing hyaluronic acid and tamarind seed polysaccharide, with a water content of 60% in a single diameter of 14.1 mm and base curve of 8.6 mm. The profile of the anterior surface is spherical across the 11-mm optic. Centrally, there is a 1.0 mm diameter zone that is optically inactive, contiguous with the optical zone. Light passes through the zone but is not intended to form a usable image. The central steep zone is at least 8.00 D steeper than the optical zone. The non-focusing central zone is intended to provide for an increased depth of focus, thus improving near and intermediate vision for the presbyopic patient.

Deseyne (vifilcon C) daily disposable soft contact lenses are proposed to be indicated for the optical correction of refractive ametropia (myopia and hyperopia) in non-diseased eyes with up to 1.00 D of astigmatism that does not interfere with visual acuity (VA).

A multicenter, randomized, active-controlled, double-masked, crossover study design will be used to compare the clinical performance of the Deseyne (vifilcon C) soft contact lens for Presbyopia EDOF (test) to the 1-Day Acuvue Moist (etafilcon A) soft contact lens for Single Vision (control). This is a 1-day crossover study (conducted over 2 visits) and will consist of approximately 75 subjects (75 study eyes [all study eyes will be right eyes]) randomly assigned in-office to wear the test or the control lens first. A 30-minute washout period will be scheduled between the crossover. Subjects must be otherwise healthy, with spectacle refraction between -6.00D and +4.00 D and astigmatism ≤1.00 D that does not interfere with VA.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 45 to 70 years
  • Presence of clear corneas
  • Correction between -6.00 and +4.00 D in the spectacle plane
  • Phakic and/or pseudophakic subjects
  • Monocular best-corrected distance visual acuity (BCDVA) of 0.1 logMAR or better in the right eye
  • Be an adapted soft contact lens wearer in each eye
  • Able and willing to attend all scheduled sessions
  • Able to read, understand, and provide written informed consent -

Exclusion criteria

  • Anisometropia (spherical equivalent >2.00 D) in either eye
  • Ocular astigmatism >1.00 D in either eye
  • Monocular BCDVA worse than 0.3 logMAR in either eye
  • Any corneal infiltrates in either eye
  • Grade ≥2 slit lamp findings during Screening in either eye
  • Any scar or neovascularization within the central 4 mm of the cornea during Screening in either eye
  • History of ocular disease (eg, dry eye disease, blepharitis, conjunctivitis, ocular herpes simplex or herpes zoster, etc.) within 30 days prior to Screening in either eye
  • History of gas-permeable lens wear within 30 days prior to Screening in either eye or history of "hard" contact lens wear within 3 months of Screening in either eye
  • History of any corneal surgery, including refractive or laser surgery, in either eye
  • Implantation or removal of absorbable punctal plug within 6 months of Screening in either eye or permanent punctal occlusion in 1 or more puncta or nasolacrimal duct obstruction in either eye
  • Use of any prescription ocular medication or any over-the-counter eyedrops within 1 week of Screening in either eye or during the period of study participation
  • Participation in any drug or device clinical investigation within 2 weeks prior to Screening or during the period of study participation
  • Women of childbearing potential (those who are not surgically sterilized or postmenopausal) who are currently pregnant or breastfeeding
  • Systemic disease or use of any systemic medications that may, in the opinion of the Investigator, interfere with normal lens wear

Treatment and study plan

Test lens

Device

The test lens is the Deseyne Daily Disposable soft contact lens

Control lens

Device

The control lens is the 1-Day AcuVue Moist Daily Disposable single vision contact lens

Primary outcomes

  1. The Primary Effectiveness Endpoint for the Study is Monocular (Study [Right] Eye Only) Photopic Negative Lens-induced Distance-corrected Depth of Focus (DOF) at the 0.2 logMAR VA Threshold.

    Time frame: Day 1

    The primary effectiveness endpoint for the study is monocular (study [right] eye only) photopic negative lens-induced distance-corrected depth of focus (DOF) at the 0.2 logMAR VA threshold.. This is accomplished by adding small incremental negative lens power over the distance best corrected vision correction until blurred vision is determined (study eye only).

Secondary outcomes

  1. Mean Monocular (Study Eye Only) Photopic Distance-corrected Intermediate Visual Acuity (DCIVA) at 66 cm

    Time frame: Day 1

    Method defines measurement of visual acuity through the distance correction contact lens measured at a distance of 66 cm from the patient.

  2. Mean Monocular (Study Eye Only) Photopic Distance-corrected Near Visual Acuity (DCNVA) at 40 cm

    Time frame: Day 1

    Method is to test visual acuity through the distance contact lens correction at 40cm from the patient.

Sponsors and collaborators

Lead sponsor

Bruno Vision Care

Industry

Collaborators

  • iuvo BioScience Operations, LLC

Registry information

Acronym: EDOF

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Nov 21, 2024
Registry last updated
Mar 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.